Drug Search Results
More Filters [+]

GSK-1795091

Alternative Names: gsk-1795091, gsk1795091, gsk 1795091
Latest Update: 2022-11-01
Latest Update Note: PubMed Publication

Product Description

 a synthetic TLR4 agonist (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32739049/)

Mechanisms of Action: TLR4 Agonist

Novel Mechanism: Yes

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-1795091

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified|Oncology Unspecified|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT03447314

P1

Completed

Oncology Solid Tumor Unspecified

2020-07-01

NCT02798978

P1

Completed

Oncology Unspecified|Healthy Volunteers

2017-10-13

Recent News Events